Introduction
Licensing and partnering transactions are the alternative to full acquisition for biotech companies seeking to monetize pipeline assets. Instead of selling the entire company, a biotech can out-license specific programs or geographic rights to pharma partners, retaining ownership of the remainder and participating in the upside through royalties. It is also the more common exit for a single asset: J.P. Morgan's 2025 biopharma deal data counted 516 licensing deals against 129 biopharma acquisitions. Licensing advisory is a core activity for healthcare bankers because the economics are complex, structures vary widely by stage and therapeutic area, and the gap between a well-structured and a poorly structured deal can be worth hundreds of millions of dollars in retained value.
Out-Licensing Economics
From the biotech's perspective, an out-licensing deal provides three types of value:
Immediate cash through upfront payments, which funds ongoing development of retained programs and extends the company's cash runway without diluting shareholders. Risk sharing by transferring some development cost and regulatory risk to the partner, which is particularly valuable for expensive late-stage trials that a biotech cannot fund alone. Commercialization capability by partnering with a company that has the sales force, payer relationships, and global infrastructure that the biotech lacks.
The trade-off is that the biotech gives up part of the licensed asset's economic value, and how much depends on development stage, therapeutic area, and negotiating leverage.
- Biobucks
The total value of a licensing deal including all contingent milestone payments and the upfront payment, expressed as a single headline number. A deal announced as "worth up to $1.5 billion" typically consists of a much smaller guaranteed upfront payment (perhaps $100-200 million) with the remainder in development, regulatory, and commercial milestones that may never be fully achieved, so bankers and investors discount biobucks heavily. Upfront cash held at about 7% of announced licensing deal value in 2025, and acquisition earnouts, which work the same way, show how little of the contingent money arrives: SRS Acquiom's 2025 life sciences study found that only 19% of biopharma milestone dollars that had come due were actually paid. The upfront payment and near-term milestones are the most meaningful indicators of deal value; distant commercial milestones are speculative.
Deal Economics by Development Stage
The economics of licensing deals shift dramatically based on how far the asset has progressed through clinical development:
| Stage | Typical Upfront | Total Biobucks | Royalty Rate | Biotech Leverage |
|---|---|---|---|---|
| Preclinical | $5-50M | $200M-1B | 3-8% | Low (high risk, unproven) |
| Phase I | $20-100M | $500M-1.5B | 5-10% | Moderate |
| Phase II | $50-300M | $800M-2.5B | 8-15% | High (de-risked data) |
| Phase III | $150M-1B+ | $1-4B | 12-20% | Very high |
The pattern is intuitive: as clinical data de-risks the asset, the biotech's negotiating leverage increases and the economics shift in the biotech's favor. A preclinical asset with no human data might command a $20 million upfront and 5% royalties. The same asset after positive Phase II data might command a $200 million upfront and 12% royalties. Deal data show the same gradient: Goodwin's 2025 review of more than 200 licensing and collaboration deals found median royalty tiers of 4.5-8% for discovery and preclinical deals against 9.3-13% for Phase 1+ deals, while J.P. Morgan's data show big pharma paying median upfronts of around $150 million for Phase II oncology programs and more than $1 billion for Phase III oncology assets. This is why bankers often advise delaying licensing talks until after a value-inflecting data readout, provided the cash runway reaches it.
Deal Structure Trends
Option-to-license structures. In an option deal, the pharma partner pays a smaller upfront for the right, but not the obligation, to take a full license after seeing clinical data. Options are a common tool rather than the default: Goodwin's 2025 deal review found that 17% of licensing and collaboration deals included an opt-in, the same share as in 2024. For the biotech, the structure trades a lower upfront for retained optionality: if the data are strong, it negotiates from strength at exercise, and if the partner walks away, rights return and the asset can be re-partnered or sold in a full M&A transaction. The cost is that a lapsed option can read to investors as a verdict on the data, even when the partner's decision reflects its own portfolio priorities. The buyer's side of option mechanics is covered in pharma licensing deals.
Geographic splits. Many biotechs retain US rights, the largest and highest-priced market (the US accounted for 53% of global pharmaceutical spending at list prices in 2025, according to IQVIA), while licensing ex-US rights to partners with established infrastructure in Europe, Japan, and other markets. Apellis used this structure in 2020: under its collaboration with Sobi, Sobi paid $250 million upfront, plus $80 million in committed development reimbursements, up to $915 million in milestones and tiered double-digit royalties, for ex-US rights to systemic pegcetacoplan, while Apellis kept US rights to the drug and worldwide rights to its ophthalmology program. Geographic splits work best when the US launch is within the biotech's reach, as in rare disease, where a small specialist sales force can cover the prescriber base.
Co-development agreements. In co-development deals, both parties share development costs and commercial economics (often 50/50 or 60/40 in the licensing partner's favor). Arcellx's 2022 collaboration with Gilead's Kite is a typical template: Kite paid $225 million upfront and made a $100 million equity investment, the companies share development and commercialization costs and split US profits 50/50, and Arcellx earns royalties on ex-US sales. Co-development offers the biotech better economics than a traditional out-license (50% of profits rather than a 10-15% royalty) but requires the biotech to fund its share of development costs, which can run to hundreds of millions of dollars for large Phase III programs.
- Net Sales Royalty
A percentage of the licensed product's net sales paid by the licensee to the licensor for the duration of the royalty term (usually set country by country, running until the later of the last valid patent claim expiring or a fixed period, often 10 years, after first commercial sale). "Net sales" means gross revenue minus returns, rebates, discounts, and government-mandated price reductions. For drugs with significant Medicaid or Medicare exposure, net sales can be 30-50% below gross sales due to mandatory rebates. Royalty rates in biotech licensing range from 3-20% of net sales depending on development stage, competitive dynamics, and the licensor's contribution to the final product.
Structuring a Deal That Protects Retained Value
The banker's job is to tie the structure to the company's capital plan: which program the license cash will fund, how far it extends the runway, and what the biotech gives up. A two-program company that cannot fund both shows the trade-off.
Once the decision to license is made, value is won or lost in the contract terms rather than the headline. Diligence obligations commit the partner to minimum development effort, reversion rights return the asset if the partner deprioritizes it, and co-promotion options let the biotech keep a commercial foothold in the US. Bankers also run a competitive process across several potential partners so offers can be compared on a probability-weighted basis, not by headline value.
Comparing those two hypothetical offers properly means discounting each payment by its probability and timing, the same discipline used in an rNPV valuation. Interviewers probe exactly this judgment when they ask about biotech strategic alternatives.
The next several articles cover specific therapeutic modalities that are driving the highest-value M&A and licensing activity in biotech: ADCs, cell and gene therapy, and emerging modalities.
